Home Medizin Eine umfassende Analyse von Immun-Checkpoint-Inhibitoren deckt endokrine Toxizitätsmuster auf

Eine umfassende Analyse von Immun-Checkpoint-Inhibitoren deckt endokrine Toxizitätsmuster auf

von NFI Redaktion


Announcement of a new publication for Acta Materia Medica journal. Immunotherapy has revolutionized cancer treatment but poses a challenge in terms of immune-related adverse events (irAEs), especially endocrine toxicity, which can significantly impact patient well-being. Existing research has often been limited and has not provided comprehensive safety profiles for various immunotherapy treatments.

The authors of this article address this gap by conducting a network meta-analysis of 55 randomized controlled trials with 32,522 patients. Using STATA to calculate the area under the cumulative ranking curve, we evaluated the safety of various immunotherapy monotherapies and combination therapies. It was found that immunotherapy increases the risk of endocrine toxicities such as hypothyroidism, hyperthyroidism, hypophysitis, thyroiditis, and adrenal insufficiency, with dual immunotherapy treatments carrying a greater risk. Specifically, inhibitors of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) like Ipilimumab are closely associated with hypophysitis, while inhibitors of programmed cell death 1 (PD-1) or programmed death-ligand 1 (PD-L1) like Pembrolizumab and Nivolumab predispose patients to thyroid-related dysfunctions like hyperthyroidism, hypothyroidism, and thyroiditis. Interestingly, Nivolumab showed no increased risk of adrenal dysfunction, unlike other immunotherapy treatments.

This study provides important evidence-based insights to optimize the benefit-risk ratio of immunotherapy treatments in clinical practice.

Source:

Journal Reference:

Ouyang, P., et al. (2024) Endocrine Toxicity of Immune Checkpoint Inhibitors: a Network Meta-analysis of Current Evidence. Acta Materia Medica. doi.org/10.15212/AMM-2023-0037.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.